Das Studienregister der UME

BI 1368-0140

A multi-centre, randomised, placebo-controlled, double-blind, parralelgroup trial to evaluate safety and efficacy of spesolimab (BI 655130) i.v. in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy

Clinical Trial Regulation (CTR) / Phase 3

NCT-Nummer: NCT06624670

DICIT

Efficacy of diclofenac added to ongoing PD-1 inhibitor therapy in metastatic melanoma patients

Clinical Trial Regulation (CTR) / Phase 2

IMA203-301

A prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate efficacy, safety, and tolerability of IMA203 versus investigator’s choice of treatment in patients with previously treated, unresectable or

Clinical Trial Regulation (CTR) / Phase 3

NCT-Nummer: NCT06743126

IMA402-101

A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-tumor Activity of IMA402, a Bispecific T Cell Engaging Receptor Molecule (TCER®) targeting PRAME, in Patients With Recurrent and/or Refractory Solid Tumors

Arzneimittelgesetz (AMG) / Phase 1

IMC-F106C-301

A Phase 3 Randomized, Controlled Study of IMC-F 106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Clinical Trial Regulation (CTR) / Phase 3

NCT-Nummer: NCT06112314

mRNA-4359-P101

Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Clinical Trial Regulation (CTR) / Phase 1, Phase 2

NCT-Nummer: NCT05533697

NAZARÉ

NAZARÉ: Concurrent optical and magnetic stimulation (COMS) for treatment of patients with chroniculcers of vascular origin in a real-world Setting including care at patient's home, a prospective randomized, controlled, Assessor blinded, Phase IV, clinical trial

Medizinproduktegesetz (MPG) /

NCT-Nummer: NCT06528873

NeoMatryx

Neoadjuvant Merkel cell carcinoma therapy (Tx) with the PD-1 Inhibitor Cemiplimab - A randomized, double-blind, placebo-controlled, non-comparative Phase II study

Clinical Trial Regulation (CTR) / Phase 2

PH-L191L2TNFSCC-06/24

A Phase 2 study of intratumoral Administration of L19IL2/L19TNF in locally advanced Cutaneous Squamous Cell Carcinoma patients progressing on or intolerant to systemic treatment

Clinical Trial Regulation (CTR) / Phase 2

PH-L19IL2TNFBCC-05/24

A Phase 2 study of intratumoral administration of L19IL2/L19TNF in locally advanced Basal Cell Carcinoma patients progressed or intolerant to systemic treatment

Clinical Trial Regulation (CTR) / Phase 2

PH-L19IL2TNFCOMB-04/24

A Phase 2 controlled randomized study of the efficacy of L19IL2 or L19TNF or L19IL2/L19TNF intralesional injections for the treatment of locally advanced basal cell carcinoma patients

Clinical Trial Regulation (CTR) / Phase 2

Philogen Intact/MeRCI

A Phase 2, Three-arm, Randomized Study of the Efficacy of Intratumorally Administered L19IL2 or L19TNF or L19IL2/L19TNF, All in Combination with Systemic Anti-PD1 Pembrolizumab, in Stage III and IV Unresectable Melanoma Patients with Resistance to or Progressing Upon Anti-PD1 Checkpoint Inhibitors and with Presence of Injectable Metastases

Clinical Trial Regulation (CTR) / Phase 2

NCT-Nummer: NCT06284590

RP1-104

Randomized, Controlled, Multicenter, Phase 3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Versus Treatment of Physician's Choice in Patients With Advanced Melanoma That Has Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment Regimen [IGNYTE-3]

Clinical Trial Regulation (CTR) / Phase 3

NCT-Nummer: NCT06264180

SKABUP

Multizentrische, prospektive, randomisierte, doppelblinde Phase III-Studie zum Vergleich der Wirksamkeit und Sicherheit der Therapie der Skabies mit zwei unterschiedlich konzentrierten Permethrin-Cremes

Clinical Trial Regulation (CTR) / Phase 3

NCT-Nummer: NCT06380452

V940-012

A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With First-Line Advanced Melanoma (INTerpath-012)

Clinical Trial Regulation (CTR) / Phase 2